2021-001445-12: A study to assess the safety and efficacy of Semaglutide and the fixed dose combination of Cilofexor and Firsocostat, alone and in combination, in subjects with Chirrhosis due to Nonalcoholic Steatohepatitis (NASH) Un estudio para para evaluar la seguridad y la eficacia de Semaglutida y la dosis fija de Cilofexor y Firsocostat, en monoterapia y en combinación, en pacientes con Cirrosis debida a Esteatohepatitis No Alcohólica (EHNA) |
|
|
| Not yet recruiting | 2 | 440 | Europe | Semaglutide B 3.0 mg/ml PDS290, Cilofexor/Firsocostat (CILO/FIR) tablets, 30/20mg, GS-9674/GS-0976, Solution for injection, Film-coated tablet | Gilead Sciences, Inc., Gilead Sciences, Inc | Nonalcoholic Steatohepatitis (NASH) Esteatohepatitis No Alcohólica (EHNA), Inflammation of the liver Inflamación del hígado, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT04971785: Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) |
|
|
| Active, not recruiting | 2 | 457 | Europe, Canada, Japan, US, RoW | Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), GS-9674/GS-0976, PTM SEMA, PTM CILO/FIR | Gilead Sciences, Novo Nordisk A/S | Nonalcoholic Steatohepatitis | 11/24 | 12/24 | | |
